1 / 8

First-Line TKI Use in EGFR Mutation-Positive NSCLC

First-Line TKI Use in EGFR Mutation-Positive NSCLC. Jürgen Wolf, MD Medical Director, Center for Integrated Oncology Köln Department I of Internal Medicine University Hospital of Cologne Bonn, Germany. Pivotal Registration Trials With EGFR TKIs in EGFR Mutation-Positive NSCLC.

leda
Télécharger la présentation

First-Line TKI Use in EGFR Mutation-Positive NSCLC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. First-Line TKI Use in EGFR Mutation-Positive NSCLC Jürgen Wolf, MD Medical Director, Center for Integrated Oncology Köln Department I of Internal Medicine University Hospital of Cologne Bonn, Germany

  2. Pivotal Registration Trials With EGFR TKIs in EGFR Mutation-Positive NSCLC CI = confidence interval; EGFR = epidermal growth factor receptor; HR = hazard ratio; NSCLC = non-small cell lung cancer; OS = overall survival; PFS = progression-free survival; TKI = tyrosine kinase inhibitor a. Fukuoka M, et al. J Clin Oncol. 2011;29(21):2866-2874; b. Rosell R, et al. Lancet Oncol. 2012;13(3):239-246; c. Yang JC, et al. ASCO 2012. Abstract LBA7500.

  3. LUX-Lung 6 Trial: Afatinib vs Chemotherapy in EGFR Mutation-Positive NSCLC • A multicenter, randomized, open-label, phase 3 trial in China, the Republic of Korea, and Thailand • Patients with: • Adenocarcinoma of the lung • Presence of EGFR mutation in the tumor tissue • Stage IIIB/IV • No prior treatment with chemotherapy for advanced/metastatic disease • No prior treatment with EGFR inhibitors • Eastern Cooperative Oncology Group performance status 0 or 1 • N = 364 Randomization 2:1 Cisplatin 75 mg/m2+ gemcitabine 1000 mg/m2IV day 1 + day 8, every 3 weeks Afatinib 40 mg once daily Primary endpoint: PFS Wu YL, et al. ASCO 2013. Abstract 8016.

  4. LUX-Lung 6 Trial: PFS • Median PFS by independent review: • 11.0 months for afatinib arm • 5.6 months for chemotherapy arm • 1-year PFS: • 47% for afatinib arm • 2% for chemotherapy arm Wu YL, et al. ASCO 2013. Abstract 8016.

  5. LUX-Lung 6 Trial: Adverse Events • Most common grade 3 adverse events associated with afatinib: • Rash, 14.2% • Diarrhea, 5.4% • Stomatitis/mucositis, 5.4% • Discontinuation rate due to treatment-related adverse events: • 5.9% of patients on afatinib • 39.8% of patients on chemotherapy • Only 2% of patients on afatinib discontinued due to rash and none due to diarrhea Wu YL, et al. ASCO 2013. Abstract 8016.

  6. LUX-Lung 7 Trial: Afatinib vs Gefitinib (Irreversible TKI vs Reversible TKI) • Patients with • Advanced adenocarcinoma of the lung • Documented common EGFR mutations (del19 or L858R) • First line (no prior treatment) • Global study: 57 sites (currently recruiting) • N = 264 Randomization Gefitinib 250 mg Afatinib40 mg Primary endpoint: PFS and disease control rate at 12 months ClinicalTrials.gov. NCT01466660.

  7. Take-Home Messages • Patients must be tested for the EGFR mutation and, if positive, receive first-line EGFR TKI • Significant improvements in PFS in first-line therapy of patients with EGFR mutation-positive NSCLC with EGFR TKI vs chemotherapy • Significant improvement in quality-of-life parameters with EGFR TKI vs chemotherapy

  8. Thank you for participating in this activity. To proceed to the Post-Test and Activity Evaluation, click on the Earn CME Credits link on this page.

More Related